209 related articles for article (PubMed ID: 32735647)
1. Treatment Options for Gonadotroph Tumors: Current State and Perspectives.
Ilie MD; Raverot G
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32735647
[TBL] [Abstract][Full Text] [Related]
2. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
3. Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.
Nakano-Tateno T; Lau KJ; Wang J; McMahon C; Kawakami Y; Tateno T; Araki T
Front Endocrinol (Lausanne); 2021; 12():624686. PubMed ID: 33841328
[TBL] [Abstract][Full Text] [Related]
4. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
5. Current medical treatment and perspective in gonadotroph tumors.
Even-Zohar N; Greenman Y
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101685. PubMed ID: 35871905
[TBL] [Abstract][Full Text] [Related]
6. [Gonadotroph pituitary adenomas].
Chanson P
Ann Endocrinol (Paris); 2000 Sep; 61(3):258-68. PubMed ID: 10970952
[TBL] [Abstract][Full Text] [Related]
7. Clinical review: Functioning gonadotroph adenomas.
Ntali G; Capatina C; Grossman A; Karavitaki N
J Clin Endocrinol Metab; 2014 Dec; 99(12):4423-33. PubMed ID: 25166722
[TBL] [Abstract][Full Text] [Related]
8. Prolactinomas in males: any differences?
Duskin-Bitan H; Shimon I
Pituitary; 2020 Feb; 23(1):52-57. PubMed ID: 31802331
[TBL] [Abstract][Full Text] [Related]
9. Updating the Landscape for Functioning Gonadotroph Tumors.
Ntali G; Capatina C
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013538
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Ceccato F; Lombardi G; Albiger N; Mazzai L; Pambuku A; Rolma G; Zagonel V; Scaroni C
Anticancer Drugs; 2019 Jun; 30(5):533-536. PubMed ID: 30986806
[TBL] [Abstract][Full Text] [Related]
11. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
[TBL] [Abstract][Full Text] [Related]
12. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R
Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
14. Refractory lactotroph adenomas.
Urwyler SA; Karavitaki N
Pituitary; 2023 Jun; 26(3):273-277. PubMed ID: 36928728
[TBL] [Abstract][Full Text] [Related]
15. Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma.
Giusti M; Bocca L; Florio T; Foppiani L; Corsaro A; Auriati L; Spaziante R; Schettini G; Giordano G
J Endocrinol Invest; 2000; 23(7):463-6. PubMed ID: 11005271
[TBL] [Abstract][Full Text] [Related]
16. Gonadotroph adenoma with secondary hypersecretion of testosterone.
Chamoun R; Layfield L; Couldwell WT
World Neurosurg; 2013 Dec; 80(6):900.e7-11. PubMed ID: 23201183
[TBL] [Abstract][Full Text] [Related]
17. Advances in the medical treatment of Cushing's syndrome.
Feelders RA; Newell-Price J; Pivonello R; Nieman LK; Hofland LJ; Lacroix A
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):300-312. PubMed ID: 30033041
[TBL] [Abstract][Full Text] [Related]
18. Medical Therapy of Aggressive Pituitary Tumors.
Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):186-193. PubMed ID: 33690871
[TBL] [Abstract][Full Text] [Related]
19. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
20. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
